The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...
Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...
The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...
WHO emphasizes integrating surveillance into national STI programs. Zoliflodacin, a novel antimicrobial agent, shows promise in treating gonorrhea, demonstrating non-inferiority to ...
Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
2h
NanoViricides, Inc. Has Filed its Quarterly Report – Subsequent Raise Has Fortified Fiscal Position
SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ...
The South African on MSN
The HIV-prevention jab is here: What you need to know…
You can now be vaccinated against HIV – but that does not mean you can be reckless, warns the Department of Health ...
Measles is popping up in pockets across the country, and with holiday travel and colder weather setting in, it’s time to be ...
Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
‘We’re going to lose this tool’: Cabell health department to end syringe distribution after 10 years
The agency that distributed nearly half of all clean syringes provided to drug users in West Virginia last year will end its ...
Health experts are alarmed as Republicans degrade the country’s pivotal HIV programs — and break promises made during Trump’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback